研究在Saraca asoca中作为ACE抑制剂的强有力的心脏保护性化合物
Sonal Prasad1, Kaiser Younis2, Owais Yousuf2
1Faculty of BioSciences, IBST, Shri Ramswaroop Memorial University, Lucknow, Deva road, Barabanki-22500, India.
Toxicology reports
|September 23, 2024
概括
萨拉卡·阿索卡 (Saraca asoca) 是一种传统的草药,由于其抗氧化剂和ACE抑制剂特性,它具有显著的心血管保护潜力. 进一步的研究证实了它在治疗心脏相关疾病方面的有效性.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 萨拉卡阿索卡 (Saraca asoca) 具有多种药用特性,包括抗氧化和抗炎作用.
- 传统上用于妇女健康,其心脏保护潜力仍未得到充分探索.
- 心血管疾病需要新的治疗药物,特别是具有抗氧化剂和自由基清除能力的药物.
研究的目的:
- 审查 Saraca asoca 的体内和体外研究,以检查其心脏保护作用.
- 探索Saraca asoca中的生物活性化合物及其在心血管健康中的作用.
- 突出Saraca asoca作为天然ACE抑制剂的来源,用于管理高血压的潜力.
主要方法:
- 在电子数据库中进行全面的文献搜索 (PubMed,谷歌学者,科学网,科学直播).
- 分析各种Saraca asoca植物部分的药理和心脏保护性质.
- 评估生物活性化合物及其作用机制,包括抗氧化剂和ACE抑制.
主要成果:
- 萨拉卡阿索卡表现出显著的抗氧化剂,抗高血压和 ACE 抑制活性.
- 来自不同植物部位的生物活性化合物有助于其心脏保护潜力.
- 在体内和体外的研究支持Saraca asoca对心血管疾病的治疗疗效.
结论:
- 萨拉卡阿索卡 (Saraca asoca) 是一种有前途的天然药物,可以保护心血管系统.
- 它丰富的生物活性化合物为开发治疗心脏病的新方法提供了潜力.
- 进一步研究Saraca asoca的心脏保护机制是有必要的.
更多相关视频
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.1K
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.3K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
492
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
492
01:26Heart Failure Drugs: Inotropic Agents
539
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
539
01:25Antihypertensive Drugs: Direct Renin Inhibitors
508
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
600
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
600